| Prospective Cohort Study to Evaluate Safety/Immunogenicity of Butantan Influenza Vaccine in Healthy Adults/Elderly (NCT02313740) | Butantan Institute | 2015-04-01 |
| Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza (NCT02369159) | BioCryst Pharmaceuticals | 2015-03-11 |
| Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season (NCT02381418) | Abbott | 2015-03-01 |
| Comparative Clinical Trial of Efficacy and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza (NCT01850446) | Materia Medica Holding | 2015-02-20 |
| Influenza Vaccination Among the Elderly Individuals (NCT02362919) | Helmholtz Centre for Infection Research | 2015-02-01 |
| A Study to Assess the Safety of ASP7374 in Adult Subjects Aged 20 or Older (NCT02366962) | UMN Pharma Inc. | 2015-02-01 |
| Single Ascending Dose Challenge Study to Determine Safety and Reactogenicity of an Influenza Challenge Virus (NCT04106817) | WCCT Global | 2015-01-19 |
| Severe Influenza Cohort (NCT02392858) | Hospices Civils de Lyon | 2015-01-16 |
| A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection (NCT02293863) | Genentech, Inc. | 2015-01-14 |
| Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults (NCT02350751) | MedImmune LLC | 2015-01-01 |
| Lower Respiratory Tract Infections Managed in Primary Care in France (NCT07416266) | Hôpital Raymond Poincaré | 2015-01-01 |
| Evaluation of the Alere i Influenza A&B Nucleic Acid Amplification Versus Xpert Flu/RSV (NCT02846311) | Fondation Hôpital Saint-Joseph | 2015-01-01 |
| Platelet Immune Responses in Aging and Influenza and Sepsis (INVACS) (NCT03010410) | Intermountain Health Care, Inc. | 2014-12-21 |
| Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031) (NCT03028987) | Stanford University | 2014-11-19 |
| Phase II Study to Assess Safety & Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by TIV (NCT02293317) | BiondVax Pharmaceuticals ltd. | 2014-11-01 |
| Study of Safety and Immunogenicity of a Quadrivalent Influenza Vaccine in Healthy Adults Age 65-75 Years (NCT02247362) | VaxInnate Corporation | 2014-11-01 |
| A Clinical Study of Treating Influenza With Liugan Shuangjie Heji (NCT02572583) | Dongfang Hospital Beijing University of Chinese Medicine | 2014-11-01 |
| System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts (NCT02266277) | University of Massachusetts, Worcester | 2014-11-01 |
| The Effect of Oseltamivir Treatment on the Yield of Polymerase Chain Reaction Test for Confirmed Influenza Infection (NCT02334514) | Rambam Health Care Campus | 2014-11-01 |
| Adult Influenza Vaccination Text Message Reminders With Electronic Health Record Alerts (NCT02284594) | Columbia University | 2014-11-01 |
| Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults (NCT02307851) | Novavax | 2014-11-01 |
| Genetic and Environmental Factors in the Response to Influenza Vaccination (NCT03088904) | Stanford University | 2014-10-03 |
| Safety and Immunogenicity of Three Seasonal Trivalent Influenza Vaccines in China Military (NCT02640989) | Center for Disease Prevention and Control of Beijing Military Region | 2014-10-01 |
| Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age (NCT02290509) | Protein Sciences Corporation | 2014-10-01 |
| Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05 (NCT02255409) | Seqirus | 2014-10-01 |
| Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico. (NCT02255279) | Novartis Vaccines | 2014-10-01 |
| Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age (NCT02242643) | GlaxoSmithKline | 2014-10-01 |
| Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects (NCT02467842) | SK Chemicals Co., Ltd. | 2014-10-01 |
| Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults (NCT02258334) | Sanofi Pasteur, a Sanofi Company | 2014-10-01 |
| An RCT of Oseltamivir in Outpatients With CPD: A Pilot Study. (NCT02282384) | McMaster University | 2014-10-01 |
| Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine (NCT02480101) | Research Institute of Influenza, Russia | 2014-10-01 |
| Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients (NCT02267733) | Yale University | 2014-10-01 |
| A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose TIV (NCT02263040) | Mount Sinai Hospital, Canada | 2014-10-01 |
| Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age (NCT02285998) | Protein Sciences Corporation | 2014-10-01 |
| Do Some Healthy Adults Consistently Have Systemic Reactions to Influenza Vaccines? (NCT02263027) | Mount Sinai Hospital, Canada | 2014-10-01 |
| Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older (NCT02218697) | GlaxoSmithKline | 2014-10-01 |
| The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection (NCT03453801) | Stanford University | 2014-09-30 |
| Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029) (NCT03028974) | Stanford University | 2014-09-17 |
| Mail Outreach To Increase Vaccination Acceptance Through Engagement (NCT02243774) | Brigham and Women's Hospital | 2014-09-01 |
| Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years (NCT02215863) | Korea University Guro Hospital | 2014-09-01 |
| Evaluation of Psychometric Testing Properties of Severity Symptom Grading Scale of Influenza Infection: Flu-PRO Stage III (NCT02302924) | Henry M. Jackson Foundation for the Advancement of Military Medicine | 2014-09-01 |
| Home Administration of FluMist by Parents/Caregivers (NCT01938170) | University of North Carolina, Chapel Hill | 2014-09-01 |
| A Study of VIS410 to Assess Safety and Pharmacokinetics (NCT02045472) | Visterra, Inc. | 2014-09-01 |
| Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China (NCT02228980) | Sanofi Pasteur, a Sanofi Company | 2014-09-01 |
| A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children (NCT02207413) | GlaxoSmithKline | 2014-08-18 |
| Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine (NCT02222870) | Sanofi Pasteur, a Sanofi Company | 2014-08-01 |
| H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo... (NCT02206464) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-07-29 |
| Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations (NCT02100436) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-06-11 |
| Fluarix/ FluLaval/ Fluarix Quadrivalent/ FluLaval Quadrivalent Vaccine Pregnancy Registry (NCT02148211) | GlaxoSmithKline | 2014-06-01 |
| Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above (NCT02126761) | Seqirus | 2014-06-01 |
| Swecrit Biobank - Blood Samples From Critically Ill Patients and Healthy Controls (NCT04974775) | Skane University Hospital | 2014-06-01 |
| A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine) (NCT02121782) | Green Cross Corporation | 2014-05-01 |
| Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults (NCT02148328) | Crucell Holland BV | 2014-05-01 |
| Zoonotic Influenza Infections of Swine Origin at Ohio Agricultural Fairs (NCT02124096) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-04-25 |
| Study to Evaluate Safety and Immunogenicity of Butantan Seasonal Influenza Vaccine - FLU-02-IB (NCT02819180) | Butantan Institute | 2014-04-01 |
| Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine (NCT02107807) | Seqirus | 2014-04-01 |
| Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults (NCT01811823) | University of Witwatersrand, South Africa | 2014-03-31 |
| Influenza Immunization in Adults Over Age 75 (NCT02200276) | Johns Hopkins University | 2014-03-01 |
| Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention (NCT02015494) | VaxInnate Corporation | 2014-03-01 |
| A Phase 1/2 Study of a Intramuscular Injection of TAK-850 in Healthy Adult Subjects (NCT02111252) | Takeda | 2014-03-01 |
| Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects (NCT01990846) | Autoimmune Technologies, LLC | 2014-03-01 |
| Safety, Tolerability and Immunogenicity of NBP607QIV in Healthy Adult Volunteers (NCT03826719) | SK Chemicals Co., Ltd. | 2014-02-17 |
| A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection (NCT01715909) | Hoffmann-La Roche | 2014-01-22 |
| A Phase 1, Open Label, Ascending Dose Cohort Study of the Pharmacokinetics of Anti-Influenza Hyperimmune Intravenous Immunoglobulin in Healthy Subjects (NCT02037282) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-01-03 |
| Characterisation of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model (NCT02525055) | Hvivo | 2014-01-01 |
| A Post-marketing Safety Study of Inactivated, Split-virion Influenza Vaccine in Subjects Aged 3 Years and Older (NCT02133456) | Centers for Disease Control and Prevention, China | 2014-01-01 |
| Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316 (NCT02026349) | MDVI, LLC | 2014-01-01 |
| Safety and Immunogenicity of Co-administration of Candidate Influenza Vaccine MVA-NP+M1 and Viroflu® Seasonal Influenza Vaccine (NCT02014168) | University of Oxford | 2014-01-01 |
| Treatment of Influenza in Routine Clinical Practice (NCT02983019) | Nearmedic Plus LLC | 2013-12-01 |
| Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults (NCT02008344) | MDVI, LLC | 2013-12-01 |
| Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old (NCT02035696) | Seqirus | 2013-12-01 |
| Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection (NCT01992276) | Crucell Holland BV | 2013-12-01 |
| The Immune Response to Influenza Vaccinations in Elderly Individuals (NCT03266237) | National University Hospital, Singapore | 2013-12-01 |
| Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot) (NCT02008578) | National Institute of Allergy and Infectious Diseases (NIAID) | 2013-12-01 |
| The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine (NCT02269852) | Sinovac Biotech Co., Ltd | 2013-12-01 |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age (NCT01999842) | GlaxoSmithKline | 2013-11-25 |
| FluLaval® Quadrivalent Pregnancy Registry (NCT02000466) | GlaxoSmithKline | 2013-11-01 |
| Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation) (NCT01959945) | Protein Sciences Corporation | 2013-11-01 |
| Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults (NCT02062281) | Jiangsu Province Centers for Disease Control and Prevention | 2013-11-01 |
| Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old (NCT01992107) | Novartis Vaccines | 2013-11-01 |
| Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older (NCT01992094) | Novartis Vaccines | 2013-11-01 |
| Impact of Influenza Vaccination in Pregnancy Video Education (NCT02151201) | The Cleveland Clinic | 2013-11-01 |
| The Impact of a Short Intervention During RSV Prophylaxis on Influenza Vaccination Rate. (NCT01985620) | Tel-Aviv Sourasky Medical Center | 2013-11-01 |
| Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age (NCT01974895) | GlaxoSmithKline | 2013-10-23 |
| Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza Challenge (NCT01938352) | Crucell Holland BV | 2013-10-02 |
| Immunogenicity of a Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Undergoing Hemodialysis (NCT02686398) | Korea University Guro Hospital | 2013-10-01 |
| Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/CALIFORNIA/66/395 (H2N2) Influenza Vaccine (NCT01982331) | PATH | 2013-10-01 |
| A Study to Evaluate Intramuscular ASP7374 (NCT01961960) | UMN Pharma Inc. | 2013-10-01 |
| Statin Therapy in Acute Influenza (NCT02056340) | Beth Israel Deaconess Medical Center | 2013-10-01 |
| Randomized Controlled Trial of LAIV vs TIV Vaccines in Schools (NCT01995851) | Dalhousie University | 2013-10-01 |
| A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications (NCT01998477) | Novartis Vaccines | 2013-10-01 |
| Study of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan (NCT01967784) | Sanofi Pasteur, a Sanofi Company | 2013-10-01 |
| Study of ASP7374, Cell-culture-derived Influenza Vaccine (NCT01961947) | UMN Pharma Inc. | 2013-10-01 |
| Brief Influenza Vaccine Education to Pregnant Women (NCT01772901) | The University of Hong Kong | 2013-10-01 |
| B-cell Immunity to Influenza (SLVP017)- Year 5, 2013 (NCT03020537) | Stanford University | 2013-10-01 |
| Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older (NCT01949090) | GlaxoSmithKline | 2013-09-25 |
| T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013 (NCT03023176) | Stanford University | 2013-09-01 |
| Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine (NCT01946425) | Sanofi Pasteur, a Sanofi Company | 2013-09-01 |
| Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults (NCT01946438) | Sanofi Pasteur, a Sanofi Company | 2013-09-01 |
| H7N9 Mix and Match With MF59 in Healthy Adults (NCT01938742) | National Institute of Allergy and Infectious Diseases (NIAID) | 2013-09-01 |